000			02036 a2200529 4500
005			20250518060931.0
264		0	_c20200910
008			202009s 0 0 eng d
022			_a2044-6055
024	7		_a10.1136/bmjopen-2019-030218 _2doi
040			_aNLM _beng _cNLM
100	1		_aKvorning Ternov, Klara
245	0	0	_aFatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol. _h[electronic resource]
260			_bBMJ open _c09 2019
300			_ae030218 p. _bdigital
500			_aPublication Type: Clinical Trial Protocol; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAndrogen Antagonists _xadverse effects
650	0	4	_aAndrostenes _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBenzamides
650	0	4	_aBlood Glucose _xmetabolism
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aDenmark
650	0	4	_aFatigue _xchemically induced
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aNeoplasm Invasiveness _xpathology
650	0	4	_aNeoplasm Staging
650	0	4	_aNitriles
650	0	4	_aPhenylthiohydantoin _xadverse effects
650	0	4	_aPrednisolone _xadverse effects
650	0	4	_aProstatic Neoplasms, Castration-Resistant _xdrug therapy
650	0	4	_aQuality of Life
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRisk Assessment
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
700	1		_aSønksen, Jens
700	1		_aFode, Mikkel
700	1		_aLindberg, Henriette
700	1		_aKistorp, Caroline Michaela
700	1		_aBisbjerg, Rasmus
700	1		_aPalapattu, Ganesh
700	1		_aØstergren, Peter Busch
773	0		_tBMJ open _gvol. 9 _gno. 9 _gp. e030218
856	4	0	_uhttps://doi.org/10.1136/bmjopen-2019-030218 _zAvailable from publisher's website
999			_c30102434 _d30102434